A N-acetylglucosaminidase mutant De10A and its application

The 11th amino acid of N-acetylglucosamine was deleted through genetic engineering technology and a De10A mutant was designed, which solved the problem of poor catalytic efficiency of existing enzymes, achieved a significant improvement in catalytic efficiency and reduced application cost. The functional food field provides a wide range of application prospects.

CN117925576BActive Publication Date: 2024-12-06YUNNAN NORMAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410096860.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-01-24
Publication Date
2024-12-06
Estimated Expiration
2044-01-24

AI Technical Summary

Technical Problem

The poor catalytic efficiency of existing N-acetylglucosidases limits its application potential in the fields of medicine and functional foods.

Method used

Through genetic engineering technology, the 11th alanine position in the amino acid sequence of N-acetylglucosamine was deleted, the mutant De10A was designed, and the expression of the recombinant expression vector and strain was expressed in E. coli BL21, which improved the catalytic efficiency of the enzyme .

Benefits of technology

The Km value of the mutant De10A is reduced, the catalytic efficiency is increased by 95%, and the affinity for substrate is increased by 250%, which reduces application costs and expands its application prospects in the field of functional food production and processing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117925576B_ABST
    Figure CN117925576B_ABST
Patent Text Reader

Abstract

The present invention discloses an N-acetylglucosaminidase mutant De10A and its application, belonging to the field of genetic engineering technology. The amino acid sequence of the mutant De10A is shown in SEQ ID NO.1, and the nucleotide sequence of the coding gene of the mutant De10A is shown in SEQ ID NO.2. The present invention solves the problem of poor catalytic efficiency of existing N-acetylglucosaminidase. The K m The value is 0.2mM and the catalytic efficiency is 2035.7s ‑1 mM ‑1 Compared with the wild enzyme opt‑HJ5NagNC, the mutant De10A has a 250% higher affinity for substrates and a 95% higher catalytic efficiency, which reduces its application cost and has broad application prospects in the field of functional food production and processing.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of genetic engineering, and specifically relates to an N-acetylglucosaminidase mutant De10A and an application thereof. Background Art

[0002] N-acetylhexosaminidase (EC 3.2.1.52) is a glycoside hydrolase that catalyzes the hydrolysis of N-acetyl-D-glucosamine (GlcNAc) and N-acetyl-D-galactosamine (GalNAc) at the non-reducing ends of oligosaccharides, glycoproteins, glycolipids and other glycoconjugates. Among them, a class of enzymes with a strong affinity for GlcNAc is called acetylglucosaminidase (GlcNAcases). Existing literature 1( et al. The FEBS Journal, 2018, 285(3): 580-598) disclosed that GlcNAcases are widely present in organisms from humans to bacteria, and play important physiological functions, including the catabolism of ganglioside storage in the human body, the regulation of fruit ripening-related softening, the renewal of chitin exoskeletons in insects, chitin utilization in bacteria, cell wall recycling and flagella formation, etc.

[0003] In the CAZY database, GlcNAcases are mainly distributed in three glycoside hydrolase families: GH3, GH20 and GH84. Among them, document 2 (Zhang et al. Appl Microbiol Biot, 2018, 102 (1): 93-103) discloses that the hydrolysis activity of GH20 family N-acetylglucosamidase on chitosan oligosaccharides is generally higher than that of other family enzymes. It is the most functionally verified and structurally analyzed enzyme in all families, and it is also the enzyme with the most potential for industrial application, but the catalytic efficiency is still poor. Therefore, new enzymes are screened or existing N-acetylglucosamidase is designed and modified to improve its catalytic efficiency. Summary of the invention

[0004] The purpose of the present invention is to provide an N-acetylglucosaminidase mutant De10A and application thereof, so as to solve the problem of poor catalytic efficiency of existing N-acetylglucosaminidase.

[0005] In order to achieve the above object, the present invention provides an N-acetylglucosaminidase mutant De10A, the amino acid sequence of the mutant is shown in SEQ ID NO.1.

[0006] The present invention provides a gene encoding the N-acetylglucosaminidase mutant De10A, and the nucleotide sequence of the gene encoding is shown in SEQ ID NO.2.

[0007] The present invention provides a recombinant expression vector comprising the N-acetylglucosaminidase mutant De10A encoding gene as described above.

[0008] Preferably, the recombinant expression vector includes pET series plasmids.

[0009] The present invention provides a recombinant expression bacterium comprising the above-mentioned N-acetylglucosaminidase mutant De10A encoding gene.

[0010] Preferably, the recombinant expression bacteria is selected from Escherichia coli BL21 (DE3).

[0011] The invention provides a method for improving the catalytic efficiency of N-acetylglucosaminidase, which comprises deleting the 11th alanine in the amino acid sequence of N-acetylglucosaminidase as shown in SEQ ID NO.3.

[0012] The present invention provides an application of the N-acetylglucosaminidase mutant De10A or a gene encoding the N-acetylglucosaminidase mutant De10A in the field of functional food production and processing.

[0013] The present invention provides an application of the above-mentioned group expression vector in the production and processing of functional foods.

[0014] The present invention provides an application of the recombinant expression bacteria in the production and processing of functional foods.

[0015] The N-acetylglucosaminidase mutant De10A of the present invention and its application solve the problem of poor catalytic efficiency of existing N-acetylglucosaminidase and have the following advantages:

[0016] The present invention utilizes genetic engineering technology to provide an N-acetylglucosaminidase mutant De10A, wherein the mutant K m The value is 0.2mM and the catalytic efficiency is 2035.7s -1 mM -1 Compared with the wild enzyme opt-HJ5NagNC, the mutant De10A has a 250% higher substrate affinity and a 95% higher catalytic efficiency, which reduces its application cost and has broad application prospects in the fields of medicine or functional foods. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 This is a diagram showing the SDS-PAGE analysis results of the wild enzyme opt-HJ5NagNC and the mutant De10A provided by the present invention.

[0018] Figure 2This is a graph showing the pH activity measurement results of the wild enzyme opt-HJ5NagNC and the mutant De10A provided by the present invention.

[0019] Figure 3 This is a graph showing the results of thermal activity assay of the wild enzyme opt-HJ5NagNC and the mutant De10A provided by the present invention.

[0020] Figure 4 This is a diagram showing the results of determination of kinetic parameters of the wild enzyme opt-HJ5NagNC and the mutant De10A provided by the present invention. DETAILED DESCRIPTION

[0021] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0022] Some experimental materials and reagents used in the following examples:

[0023] 1. Strains and vectors: Escherichia coli BL21 (DE3) and expression vector pET-22b (+) were purchased from Novagen.

[0024] 2. Enzymes and other biochemical reagents: Nickel-NTA Agarose was purchased from QIAGEN, QuickMutation TM The gene site-directed mutagenesis kit was purchased from Shanghai Biyuntian Company, p-nitrophenol-β-N-acetylglucosamine (pNPGlcNAc) was purchased from Shanghai Yuanye Company, and the other reagents were domestically produced (all available from ordinary biochemical reagent companies).

[0025] 3. Culture medium

[0026] LB medium: 10 g peptone, 5 g yeast extract, 10 g sodium chloride, add distilled water to 1000 mL, pH natural (about 7). Solid medium is based on this and 2.0% (w / v) agar is added.

[0027] The recombinant N-acetylglucosaminidase in the embodiment of the present invention is the expression product of wild-type N-acetylglucosaminidase HJ5Nag (GenBank accession number ARJ33352) inserted into the recombination region of the pEasy-E2 expression vector, and its amino acid sequence is shown in SEQ ID NO. 3. The molecular biology experimental methods not specifically described in detail in this embodiment are all carried out with reference to the specific methods listed in the book "Molecular Cloning Experiment Guide" (3rd Edition) by J. Sambrook, or according to the kit and product instructions.

[0028] Example 1 Construction and transformation of mutant De10A expression vector

[0029] The nucleotide sequence of the N-acetylglucosaminidase gene hj5nag, whose GenBank accession number is KX400857, is deleted from the signal peptide NRRRGRAIAAATVLAASLA

[0030] (AATCGTCGCCGAGGACGGGCCATCGCCGCCGCCACGGTGCTCGCCGCGTC GCTGGCG), since its GC content is as high as 72% and there are more hairpin structures, codon optimization is performed, and coding sequence 7 is introduced after its start codon, and its nucleotide sequence is shown in SEQ ID NO.7, and coding sequence 8 is introduced before its stop codon, and its nucleotide sequence is shown in SEQ ID NO.8, as shown in detail as follows:

[0031] Because the N-acetylglucosaminidase gene opt-hj5nagNC is constructed between the NdeI and XhoI restriction sites in the vector pET-22b(+), and the ATG on NdeI is used as the start codon, the introduced coding sequences 7 and 8 correspond to the nucleotide fragments of the amino acid fragments 'ELAL and KGQF', respectively, to eliminate the changes in the recombinant N-acetylglucosaminidase expression sequence caused by replacing the original vector pEasy-E2 with the current vector pET-22b(+). After optimization, the N-acetylglucosaminidase optimized gene opt-hj5nagNC with a nucleotide sequence as shown in SEQ ID NO.4 was obtained. The optimized gene opt-hj5nagNC was synthesized by Suzhou Hongxun Biotechnology Co., Ltd., and a recombinant expression plasmid pET22b-opt-hj5nagNC containing the optimized gene opt-hj5nagNC was constructed, and the recombinant expression plasmid pET22b-opt-hj5nagNC was transferred into Escherichia coli BL21 (DE3) to obtain a recombinant expression bacterium containing the optimized gene. The protein expressed by the optimized gene is the optimized wild enzyme opt-HJ5NagNC, which is the same as the amino acid HJ5Nag sequence of the recombinant N-acetylglucosaminidase in the pEasy-E2 vector, and its amino acid sequence is shown in SEQ ID NO.3.

[0032] The introduced coding sequence is as follows (5'→3'):

[0033] Coding sequence 7 (SEQ ID NO. 7): GAATTGGCACTT.

[0034] Coding sequence 8 (SEQ ID NO. 8): AAGGGACAATTC.

[0035] 1. According to the sequence of the wild enzyme optimized gene opt-hj5nagNC shown in SEQ ID NO.4 and the plasmid pET-22b-opt-hj5nagNC, the recombination primers F and R were designed using CE Design software. The specific sequences are as follows:

[0036] The recombination primer sequence is as follows (5'→3'):

[0037] F (SEQ ID NO.5):

[0038] TGTAGTCCGGCACAAAACGGCGATAACCGTTCCG.

[0039] R (SEQ ID NO.6):

[0040] GTTTTGTGCCGGACTACAACCAAGTGCCAATTC.

[0041] According to QuickMutation TM According to the manufacturer's instructions of the gene site-directed mutagenesis kit, PCR amplification was performed using the plasmid pET-22b-opt-hj5nagNC as a template to obtain the PCR product of pET-22b-de10A. The reaction procedure of the PCR amplification was as follows: pre-denaturation at 95°C for 30 min; then denaturation at 95°C for 30 sec, annealing at 60°C for 30 sec, extension at 68°C for 7 min, for a total of 20 cycles; extension and completion at 68°C for 15 min; and temporary storage at 4°C for 30 min.

[0042] 2. After the PCR reaction, add 1 μL DpnI directly to the PCR reaction system, mix well and incubate in a 37°C water bath for 5 minutes. After DpnI digestion, it can be used directly for transformation or stored at -20°C for later use.

[0043] 3. Transformation and identification: The PCR digestion product was transformed into Escherichia coli BL21 (DE3) competent cells by heat shock method. After picking a single colony for culture and preservation, a recombinant expression bacterium containing the expression vector pET-22b-de10A was obtained. It was further confirmed by sequencing by Beijing Qingke Biotechnology Co., Ltd. that the nucleotide sequence of the mutant De10A encoding gene is shown in SEQ ID NO.2. At the same time, it can be seen that the amino acid sequence of the mutant De10A is shown in SEQ ID NO.1. Compared with the amino acid sequence of the optimized wild enzyme opt-HJ5NagNC (SEQ ID NO.3), De10A deletes the 11th amino acid residue alanine in the N-terminal loop region.

[0044] Example 2 Preparation of wild enzyme opt-HJ5NagNC and mutant De10A

[0045] The recombinant expression strains containing the wild enzyme opt-HJ5NagNC and mutant De10A encoding genes were inoculated in LB (containing 100 μg mL -1 Ampicillin) culture medium, 37 ° C, 180 rpm overnight culture, to obtain an activated bacterial solution.

[0046] The activated bacterial solution was inoculated into fresh LB (containing 100 μg mL -1 Ampicillin) culture medium, culture with rapid shaking at 37°C and 180 rpm constant temperature shaker for about 2 to 3 hours. 600When the pH reaches between 0.6 and 1.0, add IPTG at a final concentration of 0.7mM for induction, and culture in a constant temperature shaker at 20℃ and 160rpm for about 20h. Centrifuge the induced bacterial solution in a low-temperature centrifuge at 4℃ and 6000rpm for 10min to collect the bacteria. Suspend the bacteria with an appropriate amount of pH=7.0McIlvaine buffer, and then ultrasonically break the bacteria in a low-temperature water bath. After the above intracellular concentrated crude enzyme solution is centrifuged at 12000rpm for 10min, the supernatant is aspirated and the target protein is affinity and eluted with Nickel-NTAAgarose and 0-500mM imidazole respectively.

[0047] like Figure 1 As shown in the figure, the SDS-PAGE analysis result of the wild enzyme opt-HJ5NagNC and the mutant De10A provided by the present invention, wherein M is a protein marker; the crude enzyme solution of opt-HJ5NagNC is the unpurified wild enzyme opt-HJ5NagNC; opt-HJ5NagNC is the purified wild enzyme opt-HJ5NagNC; and De10A is the purified mutant De10A. Figure 1 It can be seen that both the wild enzyme opt-HJ5NagNC and the mutant De10A were purified, and the product was a single band.

[0048] Example 3 Determination of properties of wild enzyme opt-HJ5NagNC and mutant De10A

[0049] 1. Activity analysis of purified wild-type enzyme opt-HJ5NagNC and mutant De10A

[0050] The activity determination method adopts the p-nitrophenol (pNP) method: the substrate pNPGlcNAc is dissolved in the buffer to a final concentration of 2 mM; the reaction system contains 50 μL of appropriate enzyme solution and 450 μL of substrate; the substrate is preheated at the reaction temperature for 5 min, then the enzyme solution is added for 10 min, and then 2 mL of 1 M Na 2 CO 3 The reaction was terminated, and the OD value was measured at a wavelength of 405 nm after cooling to room temperature; 1 enzyme activity unit (U) was defined as the amount of enzyme required to decompose the substrate to produce 1 μmol pNP per minute under given conditions.

[0051] 2. Determination of the optimal pH of the purified wild-type enzyme opt-HJ5NagNC and mutant De10A

[0052] The optimal pH of the wild enzyme and mutant was determined by a two-step method. The activity was measured at every pH unit point, and the second time at the pH unit point with the highest activity and the points 0.5 pH units to the left and right. The results can be accurately and verified when the sample volume is basically unchanged. At 30°C, the buffer was 0.1M cilvaine buffer (pH = 5.0-8.0) and 0.1M glycine-NaOH (pH = 9.0). pNPGlcNAc was used as a substrate and the reaction lasted for 10 minutes to determine the enzyme activity of the purified N-acetylglucosaminidase. First, the enzyme solution was placed in a buffer solution of pH = 5.0, 6.0, 7.0, 8.0, and 9.0 for the above enzymatic reaction. It was found that the wild enzyme opt-HJ5NagNC and the mutant De10A both had the highest enzyme activity at pH 6.0. The enzyme activity of the wild enzyme and the mutant was then determined in buffer solutions of pH = 5.5, 6.0, and 6.5, respectively.

[0053] like Figure 2 As shown in the figure, the pH activity test results of the wild enzyme opt-HJ5NagNC and the mutant De10A provided by the present invention are shown. Figure 2 It can be seen that the optimal pH of the wild enzyme opt-HJ5NagNC and the mutant De10A is 6.0. The enzyme activity of the wild enzyme opt-HJ5NagNC and the mutant De10A is the highest at pH 6.0, and the mutant De10A can maintain more than 60% enzyme activity at pH 5.0-8.0.

[0054] 3. Thermal activity assay of purified wild-type enzyme opt-HJ5NagNC and mutant De10A

[0055] The optimal temperature of the wild enzyme and mutant was determined by a two-step method. The activity was measured at each temperature interval of 10°C for the first time, and at the temperature point with the highest activity and the temperature points 5°C to the left and right for the second time. The measurement results can be accurately verified when the sample volume is basically unchanged. In a buffer solution of pH = 6.0, the enzymatic reaction was first carried out at 0-60°C, and the enzyme activity was measured every 10°C from 0°C. It was found that the wild enzyme opt-HJ5NagNC and the mutant De10A had the highest enzyme activity at 40°C. Then, the enzyme activity of the wild enzyme and mutant was measured at 35°C, 40°C and 45°C in a buffer solution of pH = 6.0.

[0056] like Figure 3 As shown in the figure, the thermal activity test results of the wild enzyme opt-HJ5NagNC and the mutant De10A provided by the present invention are shown. Figure 3 It can be seen that the optimum temperatures of the wild enzyme opt-HJ5NagNC and the mutant De10A are 45℃ and 40℃, respectively.

[0057] 4. Determination of kinetic parameters of wild-type enzyme opt-HJ5NagNC and mutant De10A

[0058] At 30°C and pH 6.0, pNPGlcNAc was used as the substrate to determine the kinetic parameters of the wild-type enzyme and the mutant. The substrate concentration was between 0.1mM and 2mM, and the reaction time was 6min. The substrate concentration was used as the horizontal axis, and the enzyme activity units per milligram of enzyme calculated according to the reaction measurement results were used as the vertical axis to draw a nonlinear fitting curve, such as Figure 4 The kinetic parameters were calculated using the Michaelis-Menten equation in the nonlinear fitting calculation method of GraphPadPrism 5.0 software. The results are shown in Table 1. Compared with the wild-type enzyme, the mutant De10A has a K m It was reduced by 250%, that is, the substrate affinity was improved and the catalytic efficiency was increased by about 95%.

[0059] Table 1 Kinetic parameters of wild-type enzymes opt-HJ5NagNC and De10A

[0060]

[0061] In summary, the present invention uses genetic engineering technology to delete the 11th amino acid alanine in the N-terminal loop region of the wild enzyme opt-HJ5NagNC to obtain the mutant De10A. The catalytic efficiency of this mutant is 2035.7s -1 mM -1 Compared with wild N-acetylglucosaminidase, the catalytic efficiency is increased by 95%. The present invention provides an N-acetylglucosaminidase mutant De10A with improved catalytic efficiency, reduces application costs, and provides effective protection for its application in the field of functional food production and processing.

[0062] Although the content of the present invention has been described in detail through the above preferred embodiments, it should be appreciated that the above description should not be considered as a limitation of the present invention. After reading the above content, it will be apparent to those skilled in the art that various modifications and substitutions of the present invention will occur. Therefore, the protection scope of the present invention should be limited by the appended claims.

Claims

1. An N-acetylglucosaminidase mutant De10A, characterized in that: The amino acid sequence of the mutant is shown in SEQ ID NO.

1.

2. A gene encoding the N-acetylglucosaminidase mutant De10A as claimed in claim 1, characterized in that: The nucleotide sequence of the coding gene is shown in SEQ ID NO.

2. 3 . A recombinant expression vector comprising the gene encoding the N-acetylglucosaminidase mutant De10A as claimed in claim 2 .

4. The recombinant expression vector according to claim 3, characterized in that The recombinant expression vector includes pET series plasmids. 5 . A recombinant expression bacterium comprising the gene encoding the N-acetylglucosaminidase mutant De10A as claimed in claim 2 .

6. The recombinant expression bacteria according to claim 5, characterized in that: The recombinant expression bacteria are selected from Escherichia coli BL21 (DE3).

7. A method for improving the catalytic efficiency of N-acetylglucosaminidase, characterized in that: The method comprises deleting the 11th alanine in the amino acid sequence of N-acetylglucosaminidase as shown in SEQ ID NO.

3.

8. Use of the N-acetylglucosaminidase mutant De10A according to claim 1 or the gene encoding the N-acetylglucosaminidase mutant De10A according to claim 2 in the field of functional food production and processing.

9. Use of the recombinant expression vector as claimed in claim 3 in the field of functional food production and processing.

10. Use of the recombinant expression bacteria as claimed in claim 5 in the field of functional food production and processing.